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AbsTrACT
Objective To examine the differential diagnostic 
significance of cerebrospinal fluid (csF) biomarkers 
reflecting alzheimer’s disease-related amyloid β (aβ) 
production and aggregation, cortical neuronal damage, 
tau pathology, damage to long myelinated axons and 
astrocyte activation, which hypothetically separates 
patients with idiopathic normal pressure hydrocephalus 
(iNph) from patients with other neurodegenerative 
disorders.
Methods The study included lumbar csF samples 
from 82 patients with iNph, 75 with vascular dementia, 
70 with parkinson’s disease, 34 with multiple system 
atrophy, 34 with progressive supranuclear palsy, 15 with 
corticobasal degeneration, 50 with alzheimer’s disease, 
19 with frontotemporal lobar degeneration and 54 
healthy individuals (hIs). We analysed soluble amyloid 
precursor protein alpha (sappα) and beta (sappβ), 
aβ species (aβ38, aβ40 and aβ42), total tau (T-tau), 
phosphorylated tau, neurofilament light and monocyte 
chemoattractant protein 1 (Mcp-1).
results patients with iNph had lower concentrations 
of tau and app-derived proteins in combination with 
elevated Mcp-1 compared with hI and the non-iNph 
disorders. T-tau, aβ40 and Mcp-1 together yielded an 
area under the curve of 0.86, differentiating iNph from 
the other disorders. a prediction algorithm consisting of 
T-tau, aβ40 and Mcp-1 was designed as a diagnostic 
tool using csF biomarkers.
Conclusions The combination of the csF biomarkers 
T-tau, aβ40 and Mcp-1 separates iNph from cognitive 
and movement disorders with good diagnostic sensitivity 
and specificity. This may have important implications for 
diagnosis and clinical research on disease mechanisms 
for iNph.
INTrOduCTION
Idiopathic normal pressure hydrocephalus (iNPH), 
clinically characterised by disturbance of gait and 
balance, cognition and continence, is one of few 
neurodegenerative disorders that can be success-
fully treated.1 Shunt surgery improves around 80% 
of the patients, but if left untreated, patients will 
deteriorate emphasising the need to diagnose and 
treat patients with iNPH without delay.2 Never-
theless, the condition remains underdiagnosed and 
undertreated3 4 in part due to lack of specific diag-
nostic tests.
Diagnosing iNPH can at times be difficult as 
similar signs and symptoms can be seen in other 
neurodegenerative conditions such as Alzheimer’s 
disease (AD), vascular dementia (VAD) of the 
subcortical type and extrapyramidal disorders such 
as Parkinson’s disease (PD) and atypical parkinso-
nian syndromes.5–8
Diagnostic markers for these disorders are few. 
In patients with iNPH, a characteristic pattern 
comprising low levels of soluble amyloid precursor 
protein (APP) α and β, amyloid β (38, 40, 42), and 
total tau (T-tau) and phosphorylated tau (P-tau) 
proteins has been identified, which seems to sepa-
rate iNPH from patients with AD, subcortical VAD 
and controls.9–13 Furthermore, these cerebrospinal 
fluid (CSF) protein pattern changes are reversed 
after shunt surgery.9 11
The pathophysiology of iNPH is related to distur-
bance of CSF dynamics and thus partly different 
from aforementioned neurodegenerative disor-
ders. The characteristic CSF protein pattern seen in 
iNPH might thus, besides being a pathophysiolog-
ical hallmark, constitute a diagnostic tool. Identifi-
cation of a pathognomonic CSF protein pattern in 
iNPH would radically strengthen diagnostic accu-
racy, thereby leading to earlier identification and 
treatment of patients with iNPH.
Aim
To validate the differential diagnostic significance 
of CSF biomarkers reflecting amyloid cascade 
function, AD-related amyloid β (Aβ) production 
and aggregation, cortical neuronal damage, tau 
pathology, damage to long myelinated axons and 
astrocyte activation. All of which hypothetically 
separates iNPH from other common neurodegen-
erative disorders
MeThOds
study populations
In all, 82 patients with iNPH were selected retro-
spectively. Patients that had received the diagnosis 
of iNPH and had undergone preoperative and 
postoperative examination were consecutively 
included. All were diagnosed at the Hydrocephalus 
Research Unit, Sahlgrenska University Hospital in 
Gothenburg, Sweden, according to international 
guidelines.6 The patients were staged according 
to the iNPH scale, and improvement was defined 
as an increase in ≥5 points on the iNPH scale on 
the postoperative exam.14 All patients received 
a ventriculo-peritoneal shunt with an adjustable 
valve and were evaluated post-surgery at median 
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8 months (IQR 6:12) by the same clinical protocol. All shunts 
were working at the time for re-evaluation.
In all, 70 patients with definite PD according to the UK Parkin-
son’s Disease Society Brain Bank clinical diagnostic criteria15; 
34 with probable multiple system atrophy (MSA) according to 
Gilman’s criteria16 ; 34 with probable or definite progressive 
supranuclear palsy (PSP) according to the National Institute of 
Neurological Disorders and Stroke and Society for Progressive 
Supranuclear Palsy, clinical criteria17 ; and 15 with probable 
corticobasal degeneration (CBD) according to Armstrong et al18 
diagnosed at the Sahlgrenska University Hospitals’ movement 
disorders unit were included.
In all, 50 patients with AD and 19 patients with frontotem-
poral lobar degeneration (FTLD) were diagnosed at the Depart-
ment of Neurology at Kuopio University Hospital, Kuopio, 
Finland. The diagnoses of AD and FTLD were set by an experi-
enced neurologist specialised in memory disorders. All patients 
in the AD group met the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association) criteria for probable 
AD.19 Patients with FTLD were clinically diagnosed according 
to Nearys’ criteria.20
In all, 75 patients with VAD were diagnosed at the Depart-
ment of Geriatric Medicine at Linköping University Hospital, 
Sweden using the International Classification of Disease 10th 
Revision criteria and subgrouped according to the Association 
Internationale pour la Recherche et l'Enseignement en Neuro-
sciences) criteria.21 The patients have been described earlier.22
In total, 54 neurologically healthy individuals (HIs) were 
included in the analysis. From Kuopio University Hospital, 20 
cognitively tested subjects with a mini mental state examination 
(MMSE) score of 26 or higher undergoing spinal anaesthesia due 
to hip or knee arthroplasty were selected.23 From the Linkoping 
University Hospital, Linköping, Sweden, 34 controls >60 years 
of age and with a MMSE score of 26 points or higher under-
going planned surgical orthopaedic intervention with spinal 
anaesthesia were selected.22
AD, FTLD, VAD, PD, PSP, MSA and CBD were together 
denoted non-iNPH disorders. Non- iNPH disorders were 
further subdivided in terms of primary dysfunction. AD, FTLD 
and VAD were named cognitive disorders, whereas PD, PSP, 
MSA and CBD formed movement disorders.
Written informed consent was obtained from all participants or 
their next of kin in agreement with the Declaration of Helsinki. 
The study was approved by the Regional Ethical Review Board 
in Gothenburg/Sweden, Kuopio/Finland and Linköping/Sweden.
CsF analyses
All CSF samples were collected via lumbar puncture with the 
patient in recumbent position, handled using a standard protocol 
and kept frozen at −80°C until analysis.
Neurofilament light concentration was measured using an 
in house ELISA as previously described in detail.24 Amyloid β 
isoforms (Aβ38, Aβ40 and Aβ42), sAPPα, sAPPβ and monocyte 
chemoattractant protein 1 (MCP-1) were analysed by electro-
chemiluminescence assays as described by the kit manufacturer 
(Meso Scale Discovery, Rockville, MD, USA).25 CSF T-tau and 
P-tau concentrations were measured using commercially avail-
able INNOTEST ELISAs as described by the kit manufacturer 
(Fujirebio, Ghent, Belgium). All analyses were performed batch-
wise in one round of experiments by board-certified laboratory 
technicians who were blinded to clinical data at the Clinical 
Neurochemistry Laboratory, Sahlgrenska University Hospital, 
Mölndal, Sweden. Between run coefficient of variation was 
below 12% for all measurements.
statistics
One-way analysis of covariance (ANCOVA) adjusted for age 
and sex was used for post-hoc analysis with Dunnett’s multiple 
comparisons test. All significance tests were two-sided and 
conducted at the 5% significance level. Univariable logistic regres-
sion analysis was performed for each individual CSF variable to 
separate iNPH versus non-iNPH disorders. Stepwise selection 
of the significant variables was used to select a multivariable 
logistic model and the chosen model was then cross-validated. 
Area under the curve (AUC-statistics) was calculated for descrip-
tion of goodness of models for iNPH versus HI, non-iNPH, 
cognitive disorders and movement disorders. Statistical analyses 
were performed using SPSS Statistics for Windows V.25 (IBM 
Corp. Released 2014. IBM SPSS Statistics for Windows, V.25.0. 
Armonk, NY, USA: IBM Corp.), SAS V.9 for Windows, SAS Insti-
tute, Cary, NC, USA and GraphPad Prism for Windows V.8.0.2 
(GraphPad Software, La Jolla, CA, USA, www. graphpad. com).
data availability statement
Any data not published within the article is available and 
anonymised data will be shared by request from any qualified 
investigator.
resulTs
In all, 48 of the 82 (58.5 %) patients with iNPH improved from 
shunt placement (≥5 points), 23 (28%) remained unchanged (-5 
to 5 points), whereas 11 (13.5 %) deteriorated (≤ points).
Patients with iNPH had, compared with HI, lower concentra-
tions of P-tau and APP-derived proteins (sAPPα, sAPPβ, Aβ38, 
Aβ40 and Aβ42) in combination with elevated MCP-1 (table 1).
Compared with the non-iNPH disorders group, iNPH was 
characterised by the same significant change; low concentration 
of tau proteins and APP-derived proteins, and elevated MCP-1 
(table 1).
The tau proteins were higher in AD and VAD than in both 
iNPH and HI. In most of the movement disorders (PD, MSA and 
CBD), the tau proteins were at the same level as in iNPH, except 
in PSP, where the P-tau was slightly elevated. These results are 
confirmative of previous studies.8
All APP-derived proteins besides Aβ42 were lower in iNPH 
compared with both the cognitive and the movement disorders 
groups. Aβ42 concentrations in iNPH were compatible to those 
in AD, whereas the other APP-derived proteins were lower in 
iNPH (table 2). In figure 1, the biomarkers are presented as indi-
vidual observations for each diagnosis.
Based on pathophysiological considerations, we combined 
a tau CSF biomarker with an APP-derived protein and the 
astroglia marker MCP-1. The model consisting of P-tau, Aβ40 
and MCP-1, revealed a high AUC 0.85, and cross-validated 0.84 
was achieved. However, after cross-validation, T-tau, instead of 
P-tau, reached the highest AUC and the final model was T-tau, 
Aβ40 and MCP-1. Optimisation yielded 0.0.00533*MCP-1–
0.00062*Aβ40–0. 000238*T-tau and in its simplified form: 
10*MCP-1-Ab40-5*T-tau. The AUC for the model chosen was 
0.86 for iNPH versus non-iNPH and the cross-validated AUC was 
0.85. Figure 2 presents receiver operating characteristic (ROC) 
curves for the simplified model and its AUC for iNPH versus HI, 
versus non-iNPH-disorders, versus dementia and versus move-
ment disorders, respectively. The highest value for separation of 
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iNPH versus non-iNPH was found in the subanalysis of iNPH 
versus cognitive disorders where AUC reached 0.92.
The diagnostic predictability of the combination of the three 
CSF biomarkers T-tau, Aβ40 and MCP-1 was very high. As 
evident from the plot, the highest probability of iNPH is for 
the combination of low T-tau and Aβ40 in combination with an 
elevated MCP-1.(figure 3).
dIsCussION
In this study, we confirm the earlier described characteristic CSF 
biochemical pattern in iNPH by means of low concentrations 
of tau proteins and APP-derived proteins in combination with 
elevated MCP-1.9
The most exciting result in this study is that the typical iNPH 
profile was not found in the other neurodegenerative disorders 
supporting the notion that the pathophysiology of iNPH is 
different from the other conditions. The CSF biomarker profile 
in iNPH indicates that the pathophysiology is characterised by 
changed metabolism of APP as well as astrocyte activation, but 
no major cortical neural damage or tau pathology.
Although not pathognomonic, the biomarker pattern seems to 
be rather specific for iNPH indicating that iNPH has a specific, 
from most neurodegenerative disorders different, pathophys-
iology. Unlike the before mentioned neurodegenerative disor-
ders, iNPH is characterised by a disturbance of CSF dynamics 
with impaired CSF absorption and enlarged ventricles. The CSF 
flow is reversed with a caudal-rostral flow through the aqueduct 
and a possible CSF absorption into the periventricular capil-
laries. A reduced cerebral perfusion has been documented in the 
periventricular tissue related to either a reduced metabolism or 
degenerative changes or both.26 27
The APPs play a role in cell signalling and are important for 
synaptic formation and repair.28 Roles in cell signalling, long-
term potentiation and cell adhesion have also been proposed29 
and the low concentrations of APP-derived proteins in CSF 
could mirror the degree of metabolic changes in the periventric-
ular tissue. The importance of the periventricular region around 
the third ventricle and frontal horns is also illustrated by symp-
toms and signs in iNPH being generated from those regions.30 
Support for a downregulated periventricular metabolism is the 
fact that symptomatology in iNPH is reversible and the changes 
in the APP-derived proteins normalise after surgical treatment of 
patients with iNPH.9 11
The low concentrations of CSF T-tau and P-tau, which are 
reversed after treatment,9 11 31 could signal a reduced cortical 
metabolism or neuronal activity. The biomarker changes seen in 
iNPH do not support any major cortical degenerative process or 
tau mis-phosphorylation in iNPH.
MCP-1 expression is involved in cerebral inflammatory 
processes and the expression in glial cells is increased in trau-
matic brain injury.32 Pathological examinations of iNPH cases 
have revealed neurodegenerative changes in the periventricular 
white matter with demyelination and astrogliosis,13 33 which 
might be the explanation for the increased MCP-1 concentration 
seen in iNPH. These degenerative changes could associate with 
the fact that untreated patients with iNPH will deteriorate over 
time.2
It has been argued that CSF biomarkers levels may be 
misleading in iNPH, possibly due to brain compression in 
iNPH.34 We have reported that amyloid precursor like protein 
1 (a substitute marker for APP production) is not affected to the 
same extent as APP proteins, arguing that it is rather the APPs 
that are downregulated than a mere reduced clearance from the 
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Table 2 CSF biomarkers in iNPH compared with non-iNPH disorders, cognitive disorders and movement disorders
iNPh Non-iNPh disorders Cognitive disorders
Movement 
disorders
n=82 n=297 n=144 n=153
T-tau (pg/mL) 245 (131) 496 (443)*** 725 (517)*** 282 (186)
P-tau (pg/mL) 32 (12) 54 (36)*** 72 (38)*** 37 (22)*
NFL (pg/mL) 1717 (1963) 1960 (2508) 2340 (3147) 1603 (1633)
Aβ38 (pg/mL) 1526 (519) 2194 (794)*** 2360 (757)*** 2037 (798)***
Aβ40 (pg/mL) 3800 (1193) 5428 (1684)*** 5889 (1610)*** 4994 (1641)***
Aβ42 (pg/mL) 364 (138) 454 (197)*** 387 (182) 517 (190)***
sAPPα (pg/mL) 446 (178) 693 (282)*** 726 (299)*** 661 (262)***
sAPPβ (pg/mL) 321 (121) 498 (188)*** 527 (193)*** 471 (179)***
MCP-1 (pg/mL) 492 (109) 416 (138)*** 442 (132)* 391 (138)***
CSF biomarkers in iNPH compared to non-iNPH disorders, cognitive disorders and movement disorders. Concentrations are given as mean and SD. Significance testing was done 
by one-way ANCOVA corrected for age and sex with Dunnett’s multiple comparisons test and is shown as *p< 0.05, **p< 0.01, ***p<0.001.
Aβ, AD-related amyloid β; AD, Alzheimer’s disease; ANCOVA, analysis of covariance; CBD, corticobasal degeneration; CSF, cerebrospinal fluid; Cognitive disorders, AD+FTLD+VAD; 
FTLD, frontotemporal lobe degeneration; MCP-1, monocyte chemoattractant protein 1; MSA, multiple system atrophy; Movement disorders, PD, MSA, PSP, CBD; NFL, 
neurofilament light; Non-iNPH disorders, AD+FTLD+VAD+PD+MSA+PSP+CBD; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; P-tau, phosphorylated tau; T-tau, 
total tau; VAD, vascular dementia; iNPH, idiopathic normal pressure hydrocephalus; sAPP, soluble amyloid precursor protein.
Figure 1 Biomarker concentrations in csF as individual values in each diagnostic group. Biomarker concentrations in csF plotted as individual values 
for each group. In each graph, values are given for hIs, iNph, aD, FTLD, VaD, pD, Msa, psp and cBD. (a) concentration of T-tau, (B) p-tau, (c) NFL, (D) 
aβ38, (e) aβ40, (F) aβ42, (G) sappα, (h) sappβ and (I) Mcp-1. Bar indicates mean value. Y-axes are broken to enhance visibility. aβ, aD-related amyloid 
β; aD, alzheimer’s disease; cBD, corticobasal degeneration; csF, cerebrospinal fluid; FTLD, frontotemporal lobar degeneration; hIs, healthy individuals; 
iNph, idiopathic normal pressure hydrocephalus; Mcp-1, monocyte chemoattractant protein 1; Msa, multiple system atrophy; NFL, neurofilament light; pD, 
parkinson’s disease; psp, progressive supranuclear palsy; p-tau, phosphorylated tau; sapp, soluble amyloid precursor protein; T-tau, total tau; VaD, vascular 
dementia.
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Figure 2 ROc curves to separate iNph with the multivariable model 
10*Mcp-1 *- aβ40–5*T-tau. ROc curves for the simplified model 
10*Mcp-1-aβ40-5*T-tau. ROc curves are given for (a) iNph versus 
hI (aUc = 0.8715), (B) iNph versus non-iNph (aUc = 0.8581), (c) 
iNph versus cognitive disorders (aUc = 0.9161) and (D) iNph versus 
movement disorders (aUc = 0.8035). aβ, aD-related amyloid β; iNph, 
iNph=idiopathic normal pressure hydrocephalus; hI, healthy control; Mcp-
1, monocyte chemoattractant protein 1; T-tau; total tau.
Figure 3 prediction plot of iNph versus non-iNph disorders. prediction 
plot showing probability of iNph. T-tau is given in four concentrations, 
aβ40 is given in eight different intervals, whereas Mcp-1 is shown as a 
continuous variable on the X-axes. estimated probability of iNph is given 
on the Y-axes. aβ, aD-related amyloid β; iNph, iNph=idiopathic normal 
pressure hydrocephalus; Mcp-1, monocyte chemoattractant protein 1; 
T-tau, total tau.
brain parenchyma to the CSF.35 This does not exclude the possi-
bility of the combination of a downregulated APP production 
and a reduced clearance from the parenchyma. Micro dialysis 
studies indicates that Aβ 1–42 levels are within a similar range 
in CSF and intersititual fluid (ISF) in patients with iNPH36 and 
a correlation between biopsy-verified Aβ load and CSF Aβ42 is 
detected in iNPH13 37 arguing that there is a relation between 
levels of APP-derived proteins in the brain parenchyma and 
sampled CSF.
There were clear differences between iNPH and the cogni-
tive and movement disorders which is also reflected by the high 
discriminative power of the CSF biomarker algorithm. The cogni-
tive disorders group had higher tau proteins than both iNPH 
and HI, whereas none of the movement disorders showed an 
elevation of tau proteins in comparison with HI. The tau protein 
levels were compatible between iNPH and the movement disor-
ders (except for in PSP where P-tau was slightly elevated when 
correcting for age and sex). These findings are in line with the 
assumption that the cognitive deficits in iNPH are not primarily 
of the cortical type. We also find the pattern of APP downregu-
lation interesting where we can see that it is only in the cogni-
tive disorders that Aβ42 is affected in isolation, which probably 
is a reflection of the amyloid plaques.38 This is clearly distin-
guished from the movement disorders and from iNPH (where 
there are low concentrations of all APP-derived proteins). There 
are numerous studies of these biomarkers that corroborate our 
results as shown in a recent review on the topic.39 Our study is, 
however, to our knowledge, the first to show this in such a large 
sample size, with multiple well-defined cohorts and with analysis 
extending to multiple APP-derived proteins at once. This makes 
it possible to examine how different the pattern of APP down-
regulation is in different neurodegenerative disorders.
The pathophysiological profile in iNPH opens up for the 
possibility of using CSF biomarkers as a tool for diagnosing 
iNPH in a mixed clinical setting, as proposed in Schirinzi et 
al.40 For that purpose, we constructed a prediction plot that can 
complement clinical and radiological examination. The high 
diagnostic predictive value of the three biomarkers separating 
iNPH from non-iNPH disorders with an AUC of 0.86 is a result 
of the different pathophysiology. There are good reasons for 
further work on the diagnostic predictability including an algo-
rithm like the one presented here and we hope to validate the 
algorithm in coming studies.
There were several patients diagnosed as iNPH who had low 
estimated probability of being diagnosed using the algorithm and 
thus it cannot be used for excluding iNPH. There are several 
obvious reasons for this dilemma. The most important problem 
is the high comorbidity seen in patients with iNPH. Clinically, 
AD and iNPH symptomatology can be found in the same patient 
that benefits from shunt surgery. Several studies have shown a 
high frequency, up to 33 %, of typical AD pathology in biop-
sies from frontal cortex in patients with iNPH.13 The presence 
of AD pathology with connected CSF biomarker changes will 
add to the iNPH biomarker pattern blurring the image. Simi-
larly, a coexisting diagnose of VAD is not unusual which will 
have an impact on the iNPH CSF biomarker pattern, reducing 
the diagnostic precision. We know that long-term outcome from 
shunt placement can be affected by the presence of comorbid-
ities and this should be taken into account for the individual 
patient. There are nevertheless multiple studies that have shown 
that comorbidity should not be used to exclude patients from 
surgery.7 12 41 42 This study was not dedicated to examine the 
prediction of outcome after surgery using the biomarkers profile 
and to this date there have not been any promising studies on 
the use of CSF biomarkers to separate responders from non-re-
sponders.10 35
Another important problem is the high frequency of vascular 
risk factors present in patients diagnosed with iNPH. Patients 
with iNPH have a heavier burden of hypertension, diabetes 
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mellitus, hyperlipidaemia, obesity, ischaemic heart disease and 
arteriosclerotic cerebrovascular disease than control groups43 
which probably will influence the typical iNPH biomarker 
pattern. The probability that a patient presenting with typical 
symptoms, signs and MR changes is suffering from iNPH should 
be close to 1 if T-tau is 200 pg/mL or lower, Aβ40 1000 pg/mL 
or lower and MCP-1 800 pg/mL or more using the suggested 
algorithm. Such a patient will probably not have any vascular 
risk factors and no co-morbidity.
We believe that this study has several strengths. The CSF 
biomarkers in iNPH are contrasted to a large material of patients 
from the most common clinical iNPH mimics. For each diag-
nosis, the patients are diagnosed at single centres and by strict 
criteria, making them highly representative for their respective 
disorders. All CSF laboratory analyses were executed at the same 
time making the CSF analyses solid. Comparisons are corrected 
for the effect of age and sex. To our knowledge, this is the first 
time that this can be presented for iNPH.
There are some limitations to this study. We have aimed at 
analysing distinct disorders. However, the diagnoses are clinical 
and are as such subject to possible false classification as we do 
not include post-mortem diagnostic verification. We also know 
that different comorbidities may be present in the groups. iNPH 
cases with presumed comorbidity were offered shunt placement 
if it was believed that the patients’ main symptomatology was 
caused by the iNPH. This may very well influence the propor-
tion of improved patients in this cohort, which was comparably 
low. It should be noted that a large amount of patients remained 
clinically unchanged, whereas we know that patients do dete-
riorate without shunt placement.2 We therefore think that the 
disease course is probably slowed by the shunt placement even if 
not reversed enough to reach the preset limit for improvement.
We are lacking comparative clinical data to stage severity in the 
different disorders. It would have been beneficial to have access 
to cognitive measurements for the dementia cases. We believe, 
nevertheless, that the different groups are clinically representa-
tive. Of special note is the large age-span in some of the groups 
(ie, PD). We made the decision to include all patients from this 
centre and made the decision that even if this would include cases 
that would not pose an iNPH-differential diagnostic problem, the 
span does mirror the clinical reality and the specialised clinics. 
The results are corrected for the possible age bias but should be 
taken into consideration when comparing absolute levels. The 
groups were unequal in numbers which might influence some 
statistical calculating but the miscalculations would rather be to 
underestimate possible differences than to exaggerate them. The 
HIs were from two different cohorts. The choice to merge the 
groups were made to enhance the group size. We believe that this 
can be done as the controls were selected using the same criteria 
but it is of course suboptimal.
CONClusIONs
The characteristic CSF biochemical pattern in iNPH by means of 
low concentrations of tau proteins and APP-derived proteins in 
combination with elevated MCP-1 was confirmed in this study 
and was shown to separate patients with iNPH from HIs and 
patients with VAD, PD, MSA, PSP, CBD, AD and FTLD.
The combination of the CSF biomarkers T-tau, Aβ40 and 
MCP-1 separates iNPH from cognitive and movement disorders 
with good diagnostic sensitivity and specificity and a prediction 
plot using these CSF biomarkers was constructed. The findings 
in this study may have important implications for diagnosis and 
clinical research on disease mechanisms for iNPH.
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